You searched for: pulmonarja (Maltesiska - Engelska)

edima pulmonarja
pulmonary oedema

mhux magħruf: ipertensjoni pulmonarja
not known: pulmonary hypertension

edima pulmonarja edima periferali
pulmonary oedema peripheral oedema

l-adenomatożi pulmonarja, fl-aħħar tliet snin, u
pulmonary adenomatosis, within the last three years, and

pde5 huwa l- aktar phosphodiesterase importanti fil-vaskulatura pulmonarja.
pde5 is the predominant phosphodiesterase in the pulmonary vasculature.

jekk tiġi kkonfermata t-tossiċità pulmonarja, il-kura għandha titwaqqaf.
if pulmonary toxicity is confirmed treatment should be discontinued.

l-effikaċja f’pazjenti b’ipertensjoni arterjali pulmonarja (pah)
efficacy in patients with pulmonary arterial hypertension (pah)

tossiċità kardjopulmonarja ( għeluq prematur tad-ductus arteriosus u ipertensjoni pulmonarja);
cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);

ipertensjoni pulmonarja bi pressjoni sistolika fl- arterji tal- pulmun > 90 mm hg.
pulmonary hypertension with a systolic pulmonary artery pressure > 90 mm hg.

ofev huwa indikat fl-adulti għall-kura tal-fibrożi pulmonarja idjopatika (ipf).
ofev is indicated in adults for the treatment of idiopathic pulmonary fibrosis (ipf).

ikollhom marda pulmonarja ostruttiva kronika (copd, marda li twassal għal tidjiq fil-pajpijiet tan- nifs);
have severe chronic obstructive pulmonary disease (copd, a disease causing narrowing of the airways);

ofev fih is-sustanza attiva nintedanib u jintuża għall-kura tal-fibrożi pulmonarja idjopatika (ipf).
ofev contains the active substance nintedanib and it is used for the treatment of idiopathic pulmonary fibrosis (ipf).

dispnea bl- isforz, epistażi, sogħla, rinorrea. waqfien respiratorju, ipoksja, konġestjoni pulmonarja, effużjoni plewrali, ażma,
common: dyspnoea exertional, epistaxis, cough, rhinorrhoea.

jekk ikun hemm sinjali ta’ edima pulmonarja meta jingħata tadalafil, għandha tiġi kkunsidrata l-possibiltà li jkun hemm l-iżvilupp ta’ mvop.
should signs of pulmonary oedema occur when tadalafil is administered, the possibility of associated pvod should be considered.

ma dehrux effetti mhux mixtieqa waqt studji kliniċi, iżda dehru f’annimali li ġew esposti għal doża daqs dik klinika u jista’ jkollhom rilevanza għall-użu kliniku, kif spjegat: vakwolazzjoni taċ-ċelluli tal- frixa, tħassir tat-tubi testikolari, ulċerazzjoni gastrointestinali, ksur tal-għadam u kallijiet, ematopojesi epatika, u fosfolipidosi pulmonarja.
adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: pancreatic islet cell vacuolation, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and calluses, hepatic haematopoiesis, and pulmonary phospholipidosis.